The Her-2/neu oncogene encode a growth factor receptor, P185. Overexpression of this protein is thought to confer a growth advantage to tumors and has been associated with an adverse outcome in Non Small Cell Lung Cancer.
This study is a case-control, cross sectional study to evaluate the clinical usefulness of soluble Her-2/neu as a marker in the diagnosis of lung cancer. Level of soluble Her-2/neu in 43 lung cancer patients and 42 age/sex matched controls, measured by an enzyme immunoassay method.
More than 93% of patients aged more than 55 years and 83% of lung cancer patients were smoker. Mean serum level of soluble Her-2/neu in cancer patients was 6.07±10.37 ngr/ml which was significantly higher than that of control (P < 0.05). Cigarette smoking has no effect on the level of soluble Her-2/neu. A cut off level of 6.1 ngr/ml revealed a high specificity (95%) for diagnosis of lung cancer, with very low sensitivity (14%). Conclusion: The results of this study show the higher level of soluble Her-2/neu in the sera of lung cancer patients with high specificity and low sensitivity for a cut off level of 6.1 ngr/ml.
The results of this study show the higher level of soluble Her-2/neu in the sera of lung cancer patients with high specificity and low sensitivity for a cut off level of 6.1 ngr/ml.
Mohammad Ghayumi, None.